Looking for more mental health CME?
Enroll in Mental Health Bootcamp, an on-demand curriculum with over 30 courses, a library of downloadable resources, and Q&A with faculty.
Learn More
This activity is part of the Frankly Speaking with Dr. Frank Domino podcast series.
Podcast
0.25 CME/CE Credit
Screening for Depression and Suicide Risk in Adolescents—Do You Know What to Do? - Frankly Speaking Ep 313Guest: Susan Feeney, DNP, FNP-BC, NP-C
Music Credit: Richard Onorato
The prevalence of anxiety and depression has been increasing in US youth over the past decade with noted increases during the pandemic. The USPSTF recently released its recommendations supporting general screening for depression in 12- to 18-year-olds. Join us while we discuss the recommendations, the basis for these recommendations, how to integrate them into practice, and some strategies on how to support adolescents and families with a positive screen.
Episode Reference and Resource Links:
- CDC Children’s Mental Health: https://www.cdc.gov/childrensmentalhealth/depression.html
i. Data and Statistics on Children’s Mental Health https://www.cdc.gov/childrensmentalhealth/data.html - Screening for Depression and Suicide Risk in Children and Adolescents - US Preventive Services Task Force Recommendations Statement; JAMA. doi:10.1001/jama.2022.16946. Published online October 11, 2022.
- US Preventive Services Task Force Recommendation Statement on Depression and Suicide Risk in Children and Adolescents: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-depression-suicide-risk-children-adolescents
Begin
Already listened on another platform?
CME/CE Information
0.25 AMA PRA Category 1 Credits™
Release Date: 1/30/2023
Expiration Date: 1/30/2025
Topics
Learning Objectives
- Identify common mental health conditions in the adolescent population
- Summarize the USPSTF recommendations for anxiety and depression screening in adolescents
Faculty
Frank J. Domino, MD
Professor, Family Medicine and Community Health,
University of Massachusetts Medical School, Worcester, MA
Susan Feeney, DNP, FNP-BC, NP-C
Assistant Professor and Coordinator of the Family Nurse Practitioner Track
UMMS GSN
Disclosures
Frank J. Domino, MD: Has disclosed no relevant financial relationships.
Susan Feeney, DNP, FNP-BC, NP-C: Has disclosed no relevant financial relationships.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
CME/CE Information
AMA PRA Category 1 Credits™
Accreditation Statement
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement
Pri-Med Institute designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Obtaining Credit
For APRNs and PAs, AANPCB and NCCPA accept AMA PRA Category 1 Credit™ as the number of hours of participation (AANPCB) or as Category 1 CME credits (NCCPA).
Supporters and Partners
Commercial Supporter
Commercial Supporter Here
Education Partner
Education Partner here
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients. Data, indications, and guidelines presented in this activity are current as of the activity release date and they are subject to change as new information is published.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions?
If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.